|

French National Database of Rare Dermatological Cancers

RECRUITINGSponsored by University Hospital, Lille
Actively Recruiting
SponsorUniversity Hospital, Lille
Started2015-11-24
Est. completion2026-12-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03210935

Summary

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : * to provide epidemiological, clinical and socio-economic characteristics of patients * to identify new clinical or epidemiological prognostic factors for these rare cancers * to evaluate the impact of various treatments on outcomes

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

Exclusion Criteria:

* Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma
* Patients refusal

Conditions4

Adnexal Tumor of SkinAdvanced Basal Cell Carcinoma Requiring Systemic TreatmentCancerMerkel Cell Carcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.